Oncopeptides

Oncopeptides has a contractual obligation to deliver warrants to the EIB upon disbursement of a loan under the renewed loan facility agreement that was entered into with the EIB on 25 November 2022 (the “Loan Agreement”). The Loan Agreement is divided into three EUR 10 million tranches, each with a maturity of five years. Oncopeptides has utilised the first tranche of the Loan Agreement and delivered 1,273,154 warrants to the EIB. According to the terms of the Loan Agreement, the EIB shall be entitled to a percentage of Oncopeptides before and after the rights issue which was completed on 3 May 2024. Existing warrants are recalculated according to the terms of the warrants and Oncopeptides has now issued additional 2,732,785 warrants to itself and transferred 1,229,753 of these warrants to the EIB. The remaining warrants will be held by Oncopeptides and may be transferred to the EIB in connection with any disbursement of remaining tranches under the Loan Agreement.
 
The board of directors of Oncopeptides has issued the warrants based on the authorization granted by the annual general meeting on 25 May 2023. The reason for the deviation from the shareholders’ preferential rights is to enable delivery of warrants to the EIB in accordance with the terms of the Loan Agreement. The warrants have a term of approximately 19 years and entitle the holder to subscribe for new ordinary shares in the company at a subscription price corresponding to the share’s quota value. Upon full subscription of all issued 9,086,985 warrants, the company’s registered share capital will increase by approximately SEK 1,009,665.05and the number of shares by 9,086,985 ordinary shares.